Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Recent advances in diabetes therapy, including the development of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, have been shown to slow the progression of renal function decline. In kidney transplant recipients, these agents have also been increasingly prescribed, and short-term renoprotective effects have been reported. However, data regarding their long-term impact on graft survival and patient survival remain limited. In this study, we compared outcomes of kidney transplant recipients with diabetic nephropathy (DMN) as the primary disease before and after the introduction of these novel antidiabetic agents.
A total of 1,497 kidney transplant recipients followed by the Osaka University Kidney Transplant Group between 2000 and 2023 were analyzed. Of these, 235 patients were classified into the DMN group and 1,262 into the non-DMN group. Each group was further divided into two time periods (2000–2009 and 2010–2023) for analysis. Propensity score matching was performed to adjust for differences in baseline characteristics.
Significant differences were observed between the two groups in recipient age, BMI, dialysis duration, prevalence of dyslipidemia, and the use of MMF and mTOR inhibitors. The 10-year and 15-year patient survival rates in the non-DMN group were 95.4% and 93.7%, respectively, whereas those in the DMN group were 92.5% and 89.6%, showing significantly lower survival in the DMN group. Similarly, graft survival at 10 and 15 years was 92.5% and 89.3% in the non-DMN group, compared with 87.7% and 80.6% in the DMN group, indicating significantly poorer graft survival among DMN recipients. These results remained consistent after propensity score matching. When analyzed by era, both patient and graft survival improved significantly in the non-DMN group over time. In contrast, in the DMN group, only graft survival showed significant improvement, while patient survival did not. The incidence of cardiovascular disease (CVD) in the DMN group was 8.9% before 2009 and 13.4% after 2010, with no significant difference between the two periods.
In conclusion, this study suggests that the introduction of novel antidiabetic agents such as SGLT2 inhibitors may be associated with improved graft survival in kidney transplant recipients with DMN. However, patient survival has not shown a corresponding improvement. These findings imply that cardiovascular events and infections remain major causes of death in this high-risk population and may not be sufficiently mitigated by current antidiabetic therapies. Further prospective studies are warranted to evaluate their potential effects on overall survival in this population.
